Press coverage about Nektar Therapeutics (NASDAQ:NKTR) has been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a news impact score of 0.24 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.9775268429743 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- BioSci Rounds Report: Unlocking Hidden Values In Omeros, Unum, And Nektar (seekingalpha.com)
- Zacks: Brokerages Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $52.42 Million (americanbankingnews.com)
- Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb (prnewswire.com)
- Analysts’ Recommendations for United Therapeutics in March 2018 (finance.yahoo.com)
- Nektar Therapeutics’ (NKTR) Buy Rating Reaffirmed at HC Wainwright (americanbankingnews.com)
Several analysts have recently commented on NKTR shares. Mizuho set a $89.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 29th. Jefferies Group raised their target price on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Canaccord Genuity reissued a “buy” rating and issued a $80.00 price objective (up from $50.00) on shares of Nektar Therapeutics in a research note on Wednesday, January 10th. BidaskClub cut shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 8th. Finally, Cowen restated a “buy” rating and issued a $101.00 target price on shares of Nektar Therapeutics in a report on Friday, March 2nd. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $62.58.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.14. The company had revenue of $95.47 million during the quarter, compared to analysts’ expectations of $36.96 million. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The firm’s revenue for the quarter was up 154.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) earnings per share. equities research analysts forecast that Nektar Therapeutics will post -1.33 earnings per share for the current fiscal year.
In other news, SVP Stephen K. Doberstein sold 2,426 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $201,212.44. Following the sale, the senior vice president now owns 67,394 shares of the company’s stock, valued at $5,589,658.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO John Nicholson sold 4,879 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $404,664.26. Following the sale, the chief operating officer now directly owns 387,657 shares in the company, valued at approximately $32,152,271.58. The disclosure for this sale can be found here. Insiders sold 369,592 shares of company stock valued at $34,241,981 in the last three months. 6.10% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/04/06/nektar-therapeutics-nktr-given-daily-media-sentiment-rating-of-0-24/2031272.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.